Q3 2024 EPS Estimates for Enlivex Therapeutics Ltd. Increased by HC Wainwright (NASDAQ:ENLV)

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) – Analysts at HC Wainwright raised their Q3 2024 EPS estimates for Enlivex Therapeutics in a research report issued on Monday, September 9th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.16) per share for the quarter, up from their previous forecast of ($0.18). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Enlivex Therapeutics’ Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.14) EPS and FY2025 earnings at ($0.58) EPS.

Enlivex Therapeutics (NASDAQ:ENLV) last released its earnings results on Friday, August 30th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.06.

Separately, EF Hutton Acquisition Co. I upgraded shares of Enlivex Therapeutics to a “strong-buy” rating in a report on Tuesday, August 27th.

Enlivex Therapeutics Stock Performance

NASDAQ:ENLV opened at $1.27 on Wednesday. Enlivex Therapeutics has a 1 year low of $1.15 and a 1 year high of $4.59. The stock has a fifty day moving average price of $1.31 and a two-hundred day moving average price of $1.93. The stock has a market capitalization of $26.46 million, a price-to-earnings ratio of -0.91 and a beta of 1.03.

Institutional Investors Weigh In On Enlivex Therapeutics

A hedge fund recently bought a new stake in Enlivex Therapeutics stock. Armistice Capital LLC purchased a new stake in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,700,571 shares of the company’s stock, valued at approximately $2,415,000. Armistice Capital LLC owned about 8.15% of Enlivex Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.